Sanofi's Generics Business To Be Sold To Private Equity Firm, Advent
Sanofi will have €1.9bn to add to its war-chest when it concludes the sale of its European generics business.
You may also be interested in...
Agnafit Bidco, comprised of Advent International and an affiliate of GIC Pte Ltd, will pay a premium for the rare disease specialist in an effort to capture value from Sobi’s planned growth.
Biopharma financing for the second quarter totaled $12.4 billion, a 25% decrease from Q1 2018. Meanwhile Q2 merger and acquisition deal value reached $101 billion, three-quarters of which came from Takeda's $79 billion takeover of major European player Shire. Alliances – totaling $13.8 billion (a significant decline from the previous quarter's $30.7 billion) – featured large partnerships in the antibody space, the biotechnology industry sector with the highest dollar volume.
Although sales of the closely-watched atopic dermatitis drug Dupixent disappointed in the first quarter, the French major sees the fall as an inventory-related blip and has high hopes that the therapy, as well as the contribution of recently acquired Bioverativ, will help fill the revenue hole left by Lantus.